Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 09 January 2017 | By Zachary Brennan
The European Medicines Agency (EMA) on Monday released for public consultation a new question and answer document focused on the risk-based prevention of cross contamination in pharmaceutical manufacturing and setting health-based exposure limits for risk identification.
The 14 questions and answers hone in on specifics such as “Do companies have to establish Health Based Exposure Limits (HBELs) for all products?” (yes), which products or active substances are highly hazardous, how the HBEL model can be applied to early phase Investigational Medicinal Products (IMPs) where limited data is available and whether HBELs need adjustment if pediatric drugs are manufactured in shared facilities with adult and animal drugs.
At the Q&A’s outset, EMA makes clear: “HBELs should be established for all products.”
Evidence that a drug product or active substance falls within any of the following five categories should result in a product being considered highly hazardous, EMA says:
In terms of establishing limits for cleaning purposes, EMA also notes that such limits should continue to be based on risk assessments and additional safety margins to help account for uncertainty in the cleaning processes and analytical variability.
“Traditional cleaning limits used by industry such as 1/1000th of minimum therapeutic dose or 10 ppm of one product in another product, may accomplish this for nonhighly hazardous products. For products classed as highly hazardous, where a thorough risk assessment can justify manufacture in shared facilities, cleaning limits should include safety factors beyond the HBEL and should not be higher than the traditional cleaning limits approach,” the Q&A says.
Questions and answers on implementation of risk based prevention of cross contamination in production and ‘Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities’ (EMA/CHMP/CVMP/SWP/169430/2012)
Tags: hazardous drug compounds, EMA guidance, HBELs